Download DDN’s “Best of Immuno-oncology” ebook to learn more about recent research in cancer immunotherapy. This ebook includes stories about antibody approaches for treating cancer, the potential of CAR-T therapies, precision cancer immunotherapy directed by immune-profiling, and cancer neoepitope discovery.
Gosia Trynka, Group Leader at The Sanger Institute and Experimental Science Director at Open Targets, talks about the importance of cellular context for translating genomic and transcriptomic insights into actionable targets.
CLEC-1 is a new therapeutic target for immuno-oncology.
The research program focuses on developing a cancer immunotherapy targeting CLEC-1, a newly identified C-type lectin receptor, to block suppressive functions of myeloid cells and restore antitumor response to T lymphocytes. Suppressive myeloid cells have the ability to accumulate in the tumor microenvironment and deregulate the immune activation of T lymphocytes.